Name | Title | Contact Details |
---|---|---|
Stephen Owusu |
Chief Executive Officer and Inventor, Co-Founder | Profile |
A deep muscle massage treatment unlike anything you’ve ever felt. Feel better, move better, and recover faster with tension and soreness relief. Therabody
ResearchPoint Global is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ōmcare is a digital health company that aims to change the way the world cares by extending the reach of caregivers, increasing medication adherence, and improving treatment outcomes through the power of remote care and two-way video technology. By partnering with pharmacies, payers, providers, and family caregivers, Ōmcare strives to help people live healthier, more vibrant, independent lives and reduce healthcare cost. Ōmcare`s first product is called the Ōmcare Home Health Hub - a web-enabled platform that dispenses medication and provides two-way, audiovisual confirmation of medication adherence while facilitating social interaction and remote telehealth care. Ōmcare exists due to the rapidly aging population; high rate of medication nonadherence; a shortage of family and professional caregivers; continued increase in health care costs; consumer preference for in-home care and aging in place; changing reimbursement for home care services; and advancements remote monitoring and wearable technology.
Uniform Data System for Medical Rehabilitation is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Buffalo, NY. To find more information about Uniform Data System for Medical Rehabilitation, please visit www.udsmr.org
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.